Recent developments from the European Society of Cardiology meeting highlight mixed results for leading players in cardiovascular therapeutics. Roivant secured a pivotal approval for its autoimmune drug, while Ionis revealed surprising trial failures in its pipeline for heart disease treatments. Concurrently, former Stanford president Marc Tessier‑Lavigne has publicly questioned revived investigations into alleged research misconduct, underscoring ongoing tensions within scientific rigor. Together, these stories illustrate the volatile landscape where market outcomes and ethical scrutiny intersect in the biopharmaceutical sector.
Exclusive BRIEF ANALYSIS
In-Depth coverage of the latest trial outcomes, stakeholder reactions, and implications for future strategy.
Read the full investigation when you subscribe to STAT+.
Subscribe
Also Read
- AstraZeneca Details Failed ATTR-CM Trial, Raising Questions About Silencer Drugs Versus Stabilizers
- A Nine-Year Case of “Functional Sneeze” Highlights a Little-Known Neurological Disorder
- Austin-Produced Jalapeño Ranch Dressing Recalled Over Undeclared Egg Content
- Dementia Risks Vary by Menopause Hormone Therapy Timing, Study Shows
